Cargando…
Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)
BACKGROUND: Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground...
Autores principales: | Stivaros, Stavros, Garg, Shruti, Tziraki, Maria, Cai, Ying, Thomas, Owen, Mellor, Joseph, Morris, Andrew A., Jim, Carly, Szumanska-Ryt, Karolina, Parkes, Laura M, Haroon, Hamied A., Montaldi, Daniela, Webb, Nicholas, Keane, John, Castellanos, Francisco X., Silva, Alcino J., Huson, Sue, Williams, Stephen, Gareth Evans, D., Emsley, Richard, Green, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824534/ https://www.ncbi.nlm.nih.gov/pubmed/29484149 http://dx.doi.org/10.1186/s13229-018-0190-z |
Ejemplares similares
-
Neuroanatomical correlates of working memory performance in Neurofibromatosis 1
por: Sawyer, Cameron, et al.
Publicado: (2022) -
Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1
por: Garg, Shruti, et al.
Publicado: (2022) -
Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1
por: Pobric, Gorana, et al.
Publicado: (2021) -
Sex bias in autism spectrum disorder in neurofibromatosis type 1
por: Garg, Shruti, et al.
Publicado: (2016) -
A Targeted, Low-Throughput Compound Screen in a Drosophila Model of Neurofibromatosis Type 1 Identifies Simvastatin and BMS-204352 as Potential Therapies for Autism Spectrum Disorder (ASD)
por: Dyson, Alex, et al.
Publicado: (2023)